Authors
Loading...
RNA-seq reveals splicing alterations and drug resistance pathways in chronic myelomonocytic leukemia with SRSF2 mutations, implicating CHD8 as a key therapeutic target.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: